Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 3/2007

01-03-2007 | ORIGINAL SCIENTIFIC REPORTS

Is Esophageal Adenocarcinoma Occurring Late After Antireflux Surgery Due to Persistent Postoperative Reflux?

Authors: Jesper Lagergren, MD, PhD, Pernilla Viklund, RN

Published in: World Journal of Surgery | Issue 3/2007

Login to get access

Abstract

Background

Gastroesophageal reflux is the main risk factor for esophageal adenocarcinoma, but there is no strong support for a protective effect of antireflux surgery. We tested the hypothesis that esophageal adenocarcinoma that develops with long latency after antireflux surgery might be due to persistent postoperative reflux.

Methods

A nationwide population-based case-control study in collaboration with 195 relevant Swedish hospital departments and tumor registries during the study period 1995–1997. Frequency-matched control persons were randomly selected from the population register. All study participants were personally interviewed regarding background data, exposures, symptoms, conditions, diseases, surgery, and medications. Differences between cases and controls in the occurrence of daily, long-standing antireflux medication 5 years or later after antireflux surgery were estimated using Fisher’s exact test.

Results

One hundred and eighty-nine out of 216 (88%) eligible cases of esophageal adenocarcinoma and 820 of 1,128 (73%) controls were prospectively enrolled. Seven (3.7%) patients and 8 controls had undergone antireflux surgery at least 5 years before the interview. All 7 case patients had Barrett’s mucosa. Four of the case patients had used postoperative antireflux medications continuously (mean duration 10.2 years), while none of the control persons reported such use (P = 0.026). There was no difference in mean body mass index between patients with and without postoperative reflux (P = 0.81). No differences between the patients and controls were found regarding age, sex, body mass index, or tobacco smoking status.

Conclusions

Esophageal adenocarcinoma occurring late after antireflux surgery might at least partly be due to persistent postoperative reflux. Further research is required to establish the role of antireflux surgery in the etiology of this tumor.
Literature
1.
Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265(10):1287–1289PubMedCrossRef
2.
Chow WH, Finkle WD, et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274(6):474–477PubMedCrossRef
3.
Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340(11):825–831PubMedCrossRef
4.
5.
Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 2002;287(15):1972–1981PubMedCrossRef
6.
Csendes A, Burdiles P, Braghetto I, et al. Adenocarcinoma appearing very late after antireflux surgery for Barrett’s esophagus: long-term follow-up, review of the literature, and addition of six patients. J Gastrointest Surg 2004;8(4):434–441PubMedCrossRef
7.
Corey KE, Schmitz SM, Shaheen NJ et al. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett’s esophagus? A meta-analysis. Am J Gastroenterol 2003;98(11):2390–2394PubMedCrossRef
8.
Ye W, Chow WH, Lagergren J, et al. Risk of adenocarcinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001;121(6):1286–1293PubMedCrossRef
9.
Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001;285(18):2331–2338PubMedCrossRef
10.
Lagergren J, Bergstrom R, Adami HO, et al. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000;133(3):165–175PubMed
11.
Brand DL, Ylvisaker JT, Gelfand M, et al. Regression of columnar esophageal (Barrett’s) epithelium after anti-reflux surgery. N Engl J Med 1980;302(15):844–848PubMedCrossRef
12.
Oberg S, Wenner J, Johansson J, et al. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 2005;242(1):49–54PubMedCrossRef
13.
Oelschlager BK, Barreca M, Chang L, et al. Clinical and pathologic response of Barrett’s esophagus to laparoscopic antireflux surgery. Ann Surg 2003;238(4):458–464; discussion 464–456PubMed
14.
Desai KM, Soper NJ, Frisella MM, et al. Efficacy of laparoscopic antireflux surgery in patients with Barrett’s esophagus. Am J Surg 2003;186(6):652–659PubMedCrossRef
15.
Spechler SJ. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. N Engl J Med 1992;326(12):786–792PubMedCrossRef
16.
Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett’s esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996;98(9):2120–2128PubMedCrossRef
17.
Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett’s esophagus and the effects of acid suppression. Gastroenterology 1999;117(2):327–335PubMedCrossRef
18.
Lagergren J, Bergstrom R, Hyrin O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 9(4):369–378
19.
Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90(2):150–155PubMedCrossRef
20.
Nilsson M, Johnsen R, Ye W, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 2003;290(1):66–72PubMedCrossRef
Metadata
Title
Is Esophageal Adenocarcinoma Occurring Late After Antireflux Surgery Due to Persistent Postoperative Reflux?
Authors
Jesper Lagergren, MD, PhD
Pernilla Viklund, RN
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 3/2007
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-006-0386-9

Other articles of this Issue 3/2007

World Journal of Surgery 3/2007 Go to the issue

OriginalPaper

Significance of Laparoscopic Splenectomy in Patients with Hypersplenism

OriginalPaper

Intraoperative Ultrasound with Palpation is Still Superior to Intra-arterial Calcium Stimulation Test in Localising Insulinoma

OriginalPaper

Appendectomy versus Antibiotic Treatment in Acute Appendicitis: A Prospective Multicenter Randomized Controlled Trial

OriginalPaper

Video-assisted Thoracoscopic Resection of a Small Pulmonary Nodule after Computed Tomography–guided Localization with a Hook-wire System

LETTERS TO THE EDITOR

Rural Surgery in Southern Sudan

INVITED COMMENTARY

Recurrence after Total Thyroidectomy for Benign Multinodular Goiter